Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK, Genmab Set “Ambitious” Development Plan For HuMax-CD20

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK signs record $2.1 billion deal with Genmab to commercialize the CD20 antibody for leukemia and rheumatoid arthritis indications.

You may also be interested in...



Genmab Reins In, Looks To Partners

Once hailed by some as a potential "European Genentech," antibody player Genmab AS is emerging far humbler from the other side of a radical strategic and financial overhaul. Hit by a series of development delays, cost overruns and some poor decision-making, the company has reined in its one-time ambition to become a fully integrated, commercial outfit.

Genmab Reins In, Looks To Partners

Once hailed by some as a potential "European Genentech," antibody player Genmab AS is emerging far humbler from the other side of a radical strategic and financial overhaul. Hit by a series of development delays, cost overruns and some poor decision-making, the company has reined in its one-time ambition to become a fully integrated, commercial outfit.

ODAC To Evaluate Strength Of Objective Response Rate Of Arzerra In CLL

Meeting at the ASCO annual meeting, FDA’s oncology panel will consider whether the effect sizes of surrogate endpoints observed in patients refractory to two drugs justify accelerated approval of GSK/Genmab’s ofatumumab.

Related Content

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel